Page 67 - JCTR-9-6

Malakar et al. | Journal of Clinical and Translational Research 2023; 9(6): 423-432 431
Cancer Cells. J Oncol Sci 2017;3:45-51. Biomed Rep 2015;3:152-8.
[34] Szwed A, Kim E, Jacinto E. Regulation and Metabolic [50] Urbanski LM, Leclair N, Anczuków O. Alternative-
Functions of mTORC1 and mTORC2. Physiol Rev splicing Defects in Cancer: Splicing Regulators and their
2021;101:1371-426. Downstream Targets, Guiding the Way to Novel Cancer
[35] Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, Therapeutics. Wiley Interdiscip Rev RNA 2018;9:e1476.
Hoffmann K, et al. Altered Glucose Metabolism in [51] Anczukow O, Krainer AR. Splicing-factor Alterations in
Childhood Pre-B Acute Lymphoblastic Leukaemia. Cancers. RNA 2016;22:1285-301.
Leukemia 2006;20:1731-7. [52] Will CL, Lührmann R. Spliceosome Structure and Function.
[36] Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cold Spring Harb Perspect Biol 2011;3:a003707.
et al. Metabolic Gatekeeper Function of B-lymphoid [53] Fredericks AM, Cygan KJ, Brown BA, Fairbrother WG.
Transcription Factors. Nature 2017;542:479-83. RNA-binding Proteins: Splicing Factors and Disease.
[37] Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Biomolecules 2015;5:893-909.
et al. Selinexor (KPT-330) Demonstrates Anti-tumor [54] Zhao W, Li Y, Yao C, Zhang G, Zhao KY, Chen W, et al.
Efficacy in Preclinical Models of Triple-negative Breast Detection of Pathogenic Isoforms of IKZF1 in Leukemic
Cancer. Breast Cancer Res 2017;19:93. Cell Lines and Acute Lymphoblastic Leukemia Samples:
[38] Kulkoyluoglu-Cotul E, Smith BP, Wrobel K, Zhao YC, Identification of a Novel Truncated IKZF1 Transcript in
Chen KL, Hieronymi K, et al. Combined Targeting SUP-B15. Cancers (Basel) 2020;12:3161.
of Estrogen Receptor Alpha and XPO1 Prevent Akt [55] Lacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F,
Activation, Remodel Metabolic Pathways and Induce Ottaviani E, et al. Expression of Spliced Oncogenic Ikaros
Autophagy to Overcome Tamoxifen Resistance. Cancers Isoforms in Philadelphia-positive Acute Lymphoblastic
(Basel) 2019;11:479. Leukemia Patients Treated with Tyrosine Kinase Inhibitors:
[39] Kawaguchi M, Aoki S, Hirao T, Morita M, Ito K. Implications for a New Mechanism of Resistance. Blood
Autophagy is an Important Metabolic Pathway to 2008;112:3847-55.
Determine Leukemia Cell Survival Following Suppression [56] Oh L, Hainaut P, Blanchet S, Ariffin H. Expression
of the Glycolytic Pathway. Biochem Biophys Res Commun of p53 N-terminal Isoforms in B-cell Precursor Acute
2016;474:188-92. Lymphoblastic Leukemia and its Correlation with
[40] Glick D, Barth S, Macleod KF. Autophagy: Cellular and Clinicopathological Profiles. BMC Cancer 2020;20:110.
Molecular Mechanisms. J Pathol 2010;221:3-12. [57] De Necochea-Campion R, Shouse GP, Zhou Q, Mirshahidi S,
[41] Rosenfeldt MT, Ryan KM. The Multiple Roles of Chen CS. Aberrant Splicing and Drug Resistance in AML.
Autophagy in Cancer. Carcinogenesis 2011;32:955-63. J Hematol Oncol 2016;9:85.
[42] Galluzzi L, Pietrocola F, Pedro JM, Amaravadi RK, [58] Housman G, Byler S, Heerboth S, Lapinska K, Longacre M,
Baehrecke EH, Cecconi F, et al. Autophagy in Malignant Snyder N, et al. Drug Resistance in Cancer: An Overview.
Transformation and Cancer Progression. EMBO J Cancers (Basel) 2014;6:1769-92.
2015;34:856-80. [59] Siegfried Z, Karni R. The Role of Alternative Splicing in
[43] Yang ZJ, Chee CE, Huang S, Sinicrope FA. The Role of Cancer Drug Resistance. Curr Opin Genet Dev 2018;48:16-21.
Autophagy in Cancer: Therapeutic Implications. Mol [60] Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K,
Cancer Ther 2011;10:1533-41. Grossmann V, et al. SF3B1 Mutations Correlated to
[44] Chen N, Karantza V. Autophagy as a Therapeutic Target in Cytogenetics and Mutations in NOTCH1, FBXW7,
Cancer. Cancer Biol Ther 2011;11:157-68. MYD88, XPO1 and TP53 in 1160 Untreated CLL Patients.
[45] Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Leukemia 2013;28:108-17.
et al. Autophagy and Chemotherapy Resistance: [61] Taylor J, Mi X, Penson AV, Paffenholz SV, Alvarez K,
A Promising Therapeutic Target for Cancer Treatment. Sigler A, et al. Safety and Activity of Selinexor in Patients
Cell Death Dis 2013;4:e838. with Myelodysplastic Syndromes or Oligoblastic Acute
[46] Losa JH, Cobo CP, Viniegra JG, Lobo VJ, Cajal SR, Myeloid Leukaemia Refractory to Hypomethylating
Sánchez-Prieto R. Role of the p38 MAPK Pathway in Agents: A Single-centre, Single-arm, Phase 2 Trial. Lancet
Cisplatin-based Therapy. Oncogene 2003;22:3998-4006. Haematol 2020;7:e566-74.
[47] Levy JM, Towers CG, Thorburn A. Targeting Autophagy in [62] Malakar P, Shilo A, Mogilevsky A, Stein I, Pikarsky E,
Cancer. Nat Rev Cancer 2017;17:528-42. Nevo Y, et al. Long Noncoding RNA MALAT1
[48] Nilsen TW, Graveley BR. Expansion of the Eukaryotic Promotes Hepatocellular Carcinoma Development by
Proteome by Alternative Splicing. Nature 2010;463:457-63. SRSF1 Upregulation and mTOR Activation. Cancer Res
[49] Wang Y, Liu J, Huang BO, Xu YM, Li J, Huang LF, 2017;77:1155-67.
et al. Mechanism of Alternative Splicing and its Regulation. [63] Ouimet M, Drouin S, Lajoie M, Caron M, St-Onge P, Gioia R,
DOI: http://dx.doi.org/10.18053/jctres.09.202306.23-00088